NJ S986 | 2018-2019 | Regular Session

Note: Carry Foward to future S1119
Note: Carry Foward to future A2789
Note: Carry Over of previous S3527

Status

Spectrum: Partisan Bill (Democrat 2-0)
Status: Introduced on January 16 2018 - 25% progression, died in committee
Action: 2018-01-16 - Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
Pending: Senate Health, Human Services and Senior Citizens Committee
Text: Latest bill text (Introduced) [HTML]

Summary

Establishes limitations on and conditions associated with prescribers' acceptance of compensation from pharmaceutical manufacturers.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Establishes limitations on and conditions associated with prescribers' acceptance of compensation from pharmaceutical manufacturers.

Sponsors


History

DateChamberAction
2018-01-16SenateIntroduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee

Same As/Similar To

S986 (Carry Over) 2018-01-16 - Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
S986 (Carry Over) 2018-01-16 - Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
S3527 (Carry Over) 2017-11-30 - Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
A4380 (Same As) 2018-09-13 - Introduced, Referred to Assembly Health and Senior Services Committee

Subjects


New Jersey State Sources


Bill Comments

feedback